Molecular biomarkers in gastric cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JNCCN.2015.0064PMID 26052595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.

  2015cited by this paper
• Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.

  2015cited by this paper
• FGF Receptors: Cancer Biology and Therapeutics

  2014cited by this paper
• Aberrant expression of SOX9 is associated with gastrokine 1 inactivation in gastric cancers

  2014cited by this paper
• Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis

  2014cited by this paper
• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers

  2014cited by this paper
• A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer.

  2014cited by this paper
• Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

  2014cited by this paper
• Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer

  2014cited by this paper
• FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

  2014cited by this paper
• Comprehensive molecular characterization of gastric adenocarcinoma

  2014cited by this paper
• Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma

  2014cited by this paper
• VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex

  2014cited by this paper
• ALDH‐1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients

  2014cited by this paper
• Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population

  2013cited by this paper
• Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

  2013cited by this paper
• FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547

  2013cited by this paper
• Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.

  2013cited by this paper
• Increased PD‐1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer

  2013cited by this paper
• Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• A novel partner of Scalloped regulates Hippo signaling via antagonizing Scalloped-Yorkie activity

  2013cited by this paper
• A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.

  2013cited by this paper
• Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.

  2013cited by this paper
• Effects of the hippo signaling pathway in human gastric cancer.

  2013cited by this paper
• Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

  2013cited by this paper
• The role of microRNAs in cancers of the upper gastrointestinal tract

  2013cited by this paper
• Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

  2013cited by this paper
• Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study

  2013cited by this paper
• Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

  2013cited by this paper
• The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression.

  2013cited by this paper
• Prognostic value of epidermal growth factor receptor in patients with gastric cancer: a meta-analysis.

  2013cited by this paper
• Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis.

  2013cited by this paper
• Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity

  2013cited by this paper
• Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

  2013cited by this paper
• Identification of CD44+ cancer stem cells in human gastric cancer.

  2013cited by this paper
• Association of HER1 amplification with poor prognosis in well differentiated gastric carcinomas

  2013cited by this paper
• Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection

  2013cited by this paper
• Gastric cancer—molecular and clinical dimensions

  2013cited by this paper
• Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts.

  2012cited by this paper
• Prognostic value of sonic hedgehog protein expression in gastric cancer.

  2012cited by this paper
• High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma

  2012cited by this paper
• Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer

  2012cited by this paper
• A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

  2012cited by this paper
• Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes.

  2012cited by this paper
• Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

  2012cited by this paper
• Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

  2012cited by this paper
• MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

  2012cited by this paper
• Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization

  2012cited by this paper
• YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• YAP oncogene overexpression supercharges colon cancer proliferation

  2012cited by this paper
• The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel

  2012cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

  2012cited by this paper
• Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

  2012cited by this paper
• B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.

  2012cited by this paper
• Anti-HER agents in gastric cancer: from bench to bedside

  2011cited by this paper
• Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination

  2011cited by this paper
• Epidermal growth factor receptor mutation in gastric cancer

  2011cited by this paper
• Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

  2011cited by this paper
• Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

  2011cited by this paper
• Elevated expression of SOX9 is related with the progression of gastric carcinoma

  2011cited by this paper
• Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• MET Expression and Amplification in Patients with Localized Gastric Cancer

  2011cited by this paper
• MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

  2011cited by this paper
• Hippo signaling: growth control and beyond

  2011cited by this paper
• Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.

  2011cited by this paper
• Sox9 marks adult organ progenitors

  2010cited by this paper
• Differential Phosphoproteomics of Fibroblast Growth Factor Signaling: Identification of Src Family Kinase-Mediated Phosphorylation Events

  2010cited by this paper
• The hippo signaling pathway in development and cancer.

  2010cited by this paper
• Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value – Conclusions from 924 Cases of Two Independent Series

  2010cited by this paper
• Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

  2010cited by this paper
• Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases

  2010cited by this paper
• Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer

  2010cited by this paper
• GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.

  2010cited by this paper
• Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

  2009cited by this paper
• The FGF family: biology, pathophysiology and therapy

  2009cited by this paper
• Notch signaling controls liver development by regulating biliary differentiation

  2009cited by this paper
• Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer

  2009cited by this paper
• Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

  2009cited by this paper
• Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

  2009cited by this paper
• The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries.

  2009cited by this paper
• Non-P 450 aldehyde oxidizing enzymes : the aldehyde dehydrogenase superfamily

  2009cited by this paper
• Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor (cid:1) Signaling

  2009cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

  2008cited by this paper
• HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

  2008cited by this paper
• Assessment of a HER2 scoring system for gastric cancer: results from a validation study

  2008cited by this paper
• TEAD mediates YAP-dependent gene induction and growth control.

  2008cited by this paper
• PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer.

  2008cited by this paper
• The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway.

  2008cited by this paper
• Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients

  2007cited by this paper
• Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport

  2007cited by this paper
• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

  2007cited by this paper

• Mapping the landscape of gastric cancer immunotherapy: Bibliometric insights into advances and hotspots

  2025cites this paper
• Promising Gastric Cancer Biomarkers—Focus on Tryptophan Metabolism via the Kynurenine Pathway

  2025influential citation
• FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects

  2024cites this paper
• Advances in understanding of role and mechanism of Hippo signaling pathway in colorectal cancer

  2023cites this paper
• A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy

  2022cites this paper
• Synaptotagmin 11 scaffolds MKK7–JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis

  2022cites this paper
• Construction and Validation of a Universal Applicable Prognostic Signature for Gastric Cancer Based on Seven Immune-Related Gene Correlated With Tumor Associated Macrophages

  2021cites this paper
• Adenocarcinoma with Mixed Subtypes in the Early and Advanced Gastric Cancer

  2021cites this paper
• CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration

  2021cites this paper
• Impact of Sites of Metastatic Dissemination on Survival in Advanced Gastroesophageal Adenocarcinoma

  2020cites this paper
• Recent Advancements in Biomarkers and Early Detection of Gastrointestinal Cancers

  2020influential citation
• Modulation of glycosyltransferase ST6Gal-I in gastric cancer-derived organoids disrupts homeostatic epithelial cell turnover

  2020cites this paper
• Biosensors and its Applications for Early Detection of Gastrointestinal Cancer

  2020cites this paper
• Biomarkers as the Promising Tools for Early Detection of Gastrointestinal Cancer

  2020cites this paper
• Molecular biology and immunology of gastric cancer peritoneal metastasis.

  2020cites this paper
• GASTRIC ADENOCARCINOMA: A DIVERSITY OF GENETIC DISORDERS N TUMOR CELLS AS A THEORETICAL BASIS FOR THE TARGETED DRUGS DEVELOPMENT

  2019cites this paper
• Oleanolic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells.

  2019cites this paper
• The diagnostic value of macrophage migration inhibitory factor, carcinoembryonic antigen, and carbohydrate antigen 19-9 in gastric cancer

  2018cites this paper
• Next generation sequencing-based emerging trends in molecular biology of gastric cancer.

  2018cites this paper
• Chk1 activation attenuates sensitivity of lapatinib in HER2‐positive gastric cancer

  2018cites this paper
• Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer

  2018cites this paper
• lncRNA GCAWKR Promotes Gastric Cancer Development by Scaffolding the Chromatin Modification Factors WDR5 and KAT2A.

  2018cites this paper
• Gastric cancer and imaging biomarkers: Part 1 – a critical review of DW-MRI and CE-MDCT findings

  2018cites this paper
• Gastric adenocarcinoma

  2017cites this paper
• Upregulated SOX9 expression indicates worse prognosis in solid tumors: a systematic review and meta-analysis

  2017cites this paper
• Advanced gastric adenocarcinoma: optimizing therapy options

  2017cites this paper
• Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer

  2017cites this paper
• Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases

  2017cites this paper
• The prognostic roles of ALDH1 isoenzymes in gastric cancer

  2016cites this paper
• Suppressive effects on cell proliferation and motility in gastric cancer SGC-7901 cells by introducing ulinastatin in vitro

  2016cites this paper
• A long non-coding RNA signature to improve prognosis prediction of gastric cancer

  2016cites this paper
• Expression of human epidermal growth factor receptor 2 and p53 in gastric cancer patients: Clinical and prognosis relevance

  2016cites this paper
• Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application

  2016cites this paper
• Association Between Tissue Inhibitor of Metalloproteinase-3 Gene Methylation and Gastric Cancer Risk: A Meta-Analysis

  2016cites this paper
• Downregulation of ALDOB is associated with poor prognosis of patients with gastric cancer

  2016cites this paper
• Conséquences de l'hypoxie sur la régulation de la signalisation HGF/SF-MET

  2015cites this paper
• A long non-coding RNA signature to improve prognosis prediction of colorectal cancer

  2014cites this paper